Language:

Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B

World journal of gastroenterology : WJG, 2015-05, Vol.21 (18), p.5524-5531

The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. 2015 ;ISSN: 1007-9327 ;EISSN: 2219-2840 ;DOI: 10.3748/wjg.v21.i18.5524 ;PMID: 25987775

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B
Author: Pan, Calvin Q ; Chan, Sing ; Trinh, Huy ; Yao, Alan ; Bae, Ho ; Lou, Lillian
Subjects: Adult ; Alanine Transaminase - blood ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Asian ; Asian Americans ; Biomarkers - blood ; Chronic ; Databases, Factual ; Drug Resistance, Viral ; Female ; Fibrosis ; hepatitis ; Hepatitis B e Antigens - blood ; Hepatitis B virus - drug effects ; Hepatitis B virus - genetics ; Hepatitis B virus - immunology ; Hepatitis B, Chronic - diagnosis ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - ethnology ; High ; Humans ; load ; Male ; Middle Aged ; patients ; Randomized Controlled Trials as Topic ; Retrospective Study ; RNA, Viral - blood ; Tenofovir ; Tenofovir - adverse effects ; Tenofovir - therapeutic use ; Time Factors ; Treatment Outcome ; United States - epidemiology ; viral ; Viral Load
Is Part Of: World journal of gastroenterology : WJG, 2015-05, Vol.21 (18), p.5524-5531
Description: AIM:To compare the efficacy and safety of tenofovir disoproxil fumarate(TDF)in Asian and non-Asian chronic hepatitis B(CHB)patients.METHODS:The efficacy and safety of the initial 48wk of treatment with TDF was compared in a posthoc analysis of combined data from 217 Asians and299 non-Asians included in Studies 102 and 103and a post-approval,open-label trial(Study 123).Patient groups were compared according to baseline hepatitis B e antigen(HBe Ag)status and viral load.The main outcome measures included the proportion of patients who achieved a hepatitis B virus(HBV)DNA level<400 copies/m L at Week 48 of treatment.Secondary measures included:HBV DNA and alanine aminotransaminase(ALT)levels over time;proportion of patients with normal ALT levels;proportion of patients with HBe Ag loss/seroconversion and proportion of patients with hepatitis B surface antigen loss/seroconversion;changes in liver histology.Safety and tolerability were evaluated by the occurrence of adverse events(AEs),serious AEs,laboratory abnormalities,discontinuation of the study drug due to AEs,or death.The primary efficacy and safety analysis set included all patients who were randomly assigned to treatment and received at least one dose of study drug.RESULTS:At week 48,similar proportions of Asians and non-Asians reached HBV DNA<400 copies/m L(96%of Asian and 97%of non-Asian patients with HBe Ag-negative CHB and 83%of Asian and 79%of non-Asian patients with HBe Ag-positive CHB had HBV DNA)and normal ALT(78%of Asian and 81%of nonAsian patients with HBe Ag-negative CHB and 71%of Asian and 74%of non-Asian patients with HBe Agpositive CHB had normal ALT).On-treatment HBV DNA decline rates were similar between Asians and nonAsians regardless of baseline HBe Ag status and viralload.HBV DNA decline during the first four weeks was2.9 log10 copies/m L in HBe Ag-negative Asians and nonAsians,and in HBe Ag-positive non-Asians,and 3.1log10 copies/m L in HBe Ag-positive Asians.HBe Ag loss and seroconversion was achieved in 14%of Asians vs 26%and 24%,respectively,in non-Asians.Liver histology improved in 77.2%of Asians and 71.5%of non-Asians.No resistance to TDF developed.No renal safety signals were observed.CONCLUSION:TDF demonstrated similar viral suppression,normalization of ALT,improvements in liver fibrosis,and no detectable resistance in Asian and non-Asian patients regardless of baseline HBe Ag status.
Publisher: United States: Baishideng Publishing Group Inc
Language: English
Identifier: ISSN: 1007-9327
EISSN: 2219-2840
DOI: 10.3748/wjg.v21.i18.5524
PMID: 25987775
Source: Open Access: PubMed Central
Geneva Foundation Free Medical Journals at publisher websites
MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B

The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. 2015 ;ISSN: 1007-9327 ;EISSN: 2219-2840 ;DOI: 10.3748/wjg.v21.i18.5524 ;PMID: 25987775

Searching Remote Databases, Please Wait